0001214659-19-003824.txt : 20190524
0001214659-19-003824.hdr.sgml : 20190524
20190524170012
ACCESSION NUMBER: 0001214659-19-003824
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190522
FILED AS OF DATE: 20190524
DATE AS OF CHANGE: 20190524
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CARTER BRUCE L A
CENTRAL INDEX KEY: 0001225503
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35921
FILM NUMBER: 19855140
MAIL ADDRESS:
STREET 1: C/O ZYMOGENETICS, INC.
STREET 2: 1201 EASTLAKE AVENUE
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Mirati Therapeutics, Inc.
CENTRAL INDEX KEY: 0001576263
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462693615
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9393 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-332-3410
MAIL ADDRESS:
STREET 1: 9393 TOWNE CENTRE DRIVE
STREET 2: SUITE 200
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
marketforms-45033.xml
PRIMARY DOCUMENT
X0306
4
2019-05-22
0001576263
Mirati Therapeutics, Inc.
MRTX
0001225503
CARTER BRUCE L A
C/O MIRATI THERAPEUTICS, INC
9393 TOWNE CENTRE DRIVE, STE 200
SAN DIEGO
CA
92121
true
false
false
false
Common Stock
2019-05-22
4
M
false
3000
6.78
A
3000
D
Common Stock
2019-05-22
4
S
false
3000
75.1989
D
0
D
Non-Qualified Stock Option (right to buy)
6.78
2019-05-22
4
M
false
3000
0
D
2026-09-26
Common Stock
3000
19000
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2018.
This transaction was executed in multiple trades at prices ranging from $74.81 to $75.57. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The shares subject to the Option vest and become exercisable in 36 equal monthly installments following the date of grant.
/s/ Vickie Reed, Attorney-in-Fact
2019-05-24